LBRX debuts as public biotech with Phase 3 schizophrenia trial underway, $395M raised

Filed March 26, 2026 · Period ending December 31, 2025 · ~2 min read

Key Changes

• high

  Phase 3 schizophrenia trial initiated March 2026 with 460 patients across 25 U.S. sites; topline data expected second half 2027. Positive Phase 2 results (January 2025) may count as one of two pivotal trials needed for FDA approval, potentially enabling NDA submission with single Phase 3 success.

  Business: Phase 3 trial initiation verify on EDGAR →
• high

  Material weaknesses in internal controls disclosed: insufficient qualified accounting staff, inadequate segregation of duties, and improper IT user access controls affecting substantially all financial statement areas. Management concluded disclosure controls and financial reporting controls were not effective as of December 31, 2025.

  Controls & Procedures verify on EDGAR →
• high

  Company raised $302.3M net in September 2025 IPO plus $100M private placement in February 2026. Cash runway projected into Q2 2029, covering planned Phase 3 schizophrenia readout (2H 2027) and Phase 2 bipolar depression readout (Q1 2028) without additional financing.

  MD&A: Liquidity verify on EDGAR →